Efficacy and Safety of Diclofenac Sodium Gel (DSG) in Knee Osteoarthritis
Launched by NOVARTIS · Jan 24, 2007
Trial Information
Current as of July 24, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Osteoarthritis of the knee
- Exclusion Criteria:
- • Other rheumatic disease, such as rheumatoid arthritis
- • Active gastrointestinal ulcer during the last year
- • Known allergy to analgesic drugs
- • Other protocol defined inclusion/exclusion criteria may apply.
About Novartis
Novartis is a global healthcare company based in Switzerland, dedicated to reimagining medicine to improve and extend people's lives. With a strong focus on innovative pharmaceuticals, Novartis engages in the research, development, and commercialization of a wide range of therapies across various therapeutic areas, including oncology, cardiology, immunology, and neuroscience. The company is committed to advancing clinical research through rigorous trials that prioritize patient safety and efficacy, aiming to deliver groundbreaking treatments and solutions that address unmet medical needs worldwide. Novartis's commitment to innovation and collaboration positions it at the forefront of the biopharmaceutical industry, driving advancements that enhance patient care and health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Warwick, Rhode Island, United States
Stuart, Florida, United States
Fall River, Massachusetts, United States
Columbus, Ohio, United States
San Antonio, Texas, United States
Kansas City, Missouri, United States
Grand Island, Nebraska, United States
Kingsport, Tennessee, United States
St. Louis, Missouri, United States
Raleigh, North Carolina, United States
Santa Maria, California, United States
Amarillo, Texas, United States
Philadelphia, Pennsylvania, United States
Wheaton, Maryland, United States
Virginia Beach, Virginia, United States
Milwaukee, Wisconsin, United States
Brooklyn Center, Minnesota, United States
San Antonio, Texas, United States
Gainesville, Florida, United States
Jupiter, Florida, United States
New Port Richey, Florida, United States
Pembroke Pines, Florida, United States
Port Orange, Florida, United States
Boise, Idaho, United States
Bensalem, Pennsylvania, United States
Erie, Pennsylvania, United States
Feasterville, Pennsylvania, United States
Havertown, Pennsylvania, United States
Anderson, South Carolina, United States
Sugar Land, Texas, United States
Newport News, Virginia, United States
Dallas, Texas, United States
Phoenix, Arizona, United States
Ormond Beach, Florida, United States
Perrysburg, Ohio, United States
Fair Oaks, California, United States
Munster, Indiana, United States
Wichita, Kansas, United States
Hollywood, Florida, United States
Plantation, Florida, United States
Miami, Florida, United States
Largo, Florida, United States
Mobile, Alabama, United States
Tallassee, Alabama, United States
Chandler, Arizona, United States
Arkansas City, Arkansas, United States
Beverly Hills, California, United States
Carmichael, California, United States
Fresno, California, United States
Santa Barbara, California, United States
Stratford, Connecticut, United States
Delray Beach, Florida, United States
Opa Locka, Florida, United States
Pembroke Pines, Florida, United States
Pinellas Park, Florida, United States
Newton, Kansas, United States
New Orleans, Louisiana, United States
Baltimore, Maryland, United States
Cadillac, Michigan, United States
Blackwood, New Jersey, United States
Cleveland, Ohio, United States
Mogadore, Ohio, United States
Austin, Texas, United States
Spokane, Washington, United States
Patients applied
Trial Officials
Roy Altman, MD
Principal Investigator
University of California, in Los Angeles, Division of Rheumatology, 310 206 7866
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials